Concizumab prophylaxis in persons with hemophilia A or B with inhibitors
Standard
Concizumab prophylaxis in persons with hemophilia A or B with inhibitors : patient-reported outcome results from the phase 3 explorer7 study. / Tran, Huyen; von Mackensen, Sylvia; Abraham, Aby; Castaman, Giancarlo; Hampton, Kingsley; Knoebl, Paul; Linari, Silvia; Odgaard-Jensen, Jan; Neergaard, Jesper Skov; Stasyshyn, Oleksandra; Thaung Zaw, Jay Jay; Zulfikar, Bulent; Shapiro, Amy.
in: RES PRACT THROMB HAE, Jahrgang 8, Nr. 4, 05.2024, S. 102476.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Concizumab prophylaxis in persons with hemophilia A or B with inhibitors
T2 - patient-reported outcome results from the phase 3 explorer7 study
AU - Tran, Huyen
AU - von Mackensen, Sylvia
AU - Abraham, Aby
AU - Castaman, Giancarlo
AU - Hampton, Kingsley
AU - Knoebl, Paul
AU - Linari, Silvia
AU - Odgaard-Jensen, Jan
AU - Neergaard, Jesper Skov
AU - Stasyshyn, Oleksandra
AU - Thaung Zaw, Jay Jay
AU - Zulfikar, Bulent
AU - Shapiro, Amy
N1 - © 2024 The Authors.
PY - 2024/5
Y1 - 2024/5
N2 - BACKGROUND: Patient-reported outcomes (PROs) reflect patient perceptions of disease and treatment and are important for evaluating new therapies.OBJECTIVES: Evaluate the effects of once-daily concizumab prophylaxis on health-related quality of life (HRQoL), treatment burden, and treatment preference in males aged ≥12 years with hemophilia A/B with inhibitors.METHODS: Patients enrolled in the multicenter, open-label explorer7 phase 3 study (ClinicalTrials.gov identifier: NCT04083781) were randomized to receive no prophylaxis (arm 1) or concizumab prophylaxis (arm 2) or were nonrandomly allocated to concizumab prophylaxis (arms 3 and 4). The study included questionnaires to assess patients' perception of HRQoL (Haemophilia Quality of Life Questionnaire for Adults), treatment burden (Hemophilia Treatment Experience Measure), and treatment preference (Haemophilia Patient Preference Questionnaire).RESULTS: The estimated treatment difference between patients receiving concizumab prophylaxis vs no prophylaxis at week 24 for Haemophilia Quality of Life Questionnaire for Adults "total score" was -22.6 points (95% CI, -42.5; -2.7), directionally favoring patients receiving concizumab prophylaxis. For Hemophilia Treatment Experience Measure "total score," the estimated treatment difference was -19.9 points (95% CI, -34.3, -5.6) in favor of concizumab vs no prophylaxis. The majority of patients receiving concizumab expressed a preference for concizumab over their previous treatment, the main reasons being "fewer bleeds," "require less time," and "less painful to inject." Across all PROs, there were less responses collected than anticipated, limiting interpretations.CONCLUSION: PROs collected during the explorer7 study showed improvements in some domains of HRQoL, treatment burden, and patient treatment preference in persons with hemophilia A or B with inhibitors receiving concizumab prophylaxis compared with no prophylaxis.
AB - BACKGROUND: Patient-reported outcomes (PROs) reflect patient perceptions of disease and treatment and are important for evaluating new therapies.OBJECTIVES: Evaluate the effects of once-daily concizumab prophylaxis on health-related quality of life (HRQoL), treatment burden, and treatment preference in males aged ≥12 years with hemophilia A/B with inhibitors.METHODS: Patients enrolled in the multicenter, open-label explorer7 phase 3 study (ClinicalTrials.gov identifier: NCT04083781) were randomized to receive no prophylaxis (arm 1) or concizumab prophylaxis (arm 2) or were nonrandomly allocated to concizumab prophylaxis (arms 3 and 4). The study included questionnaires to assess patients' perception of HRQoL (Haemophilia Quality of Life Questionnaire for Adults), treatment burden (Hemophilia Treatment Experience Measure), and treatment preference (Haemophilia Patient Preference Questionnaire).RESULTS: The estimated treatment difference between patients receiving concizumab prophylaxis vs no prophylaxis at week 24 for Haemophilia Quality of Life Questionnaire for Adults "total score" was -22.6 points (95% CI, -42.5; -2.7), directionally favoring patients receiving concizumab prophylaxis. For Hemophilia Treatment Experience Measure "total score," the estimated treatment difference was -19.9 points (95% CI, -34.3, -5.6) in favor of concizumab vs no prophylaxis. The majority of patients receiving concizumab expressed a preference for concizumab over their previous treatment, the main reasons being "fewer bleeds," "require less time," and "less painful to inject." Across all PROs, there were less responses collected than anticipated, limiting interpretations.CONCLUSION: PROs collected during the explorer7 study showed improvements in some domains of HRQoL, treatment burden, and patient treatment preference in persons with hemophilia A or B with inhibitors receiving concizumab prophylaxis compared with no prophylaxis.
U2 - 10.1016/j.rpth.2024.102476
DO - 10.1016/j.rpth.2024.102476
M3 - SCORING: Journal article
C2 - 39099801
VL - 8
SP - 102476
JO - RES PRACT THROMB HAE
JF - RES PRACT THROMB HAE
SN - 2475-0379
IS - 4
ER -